CHF392.00
2.49% yesterday
SIX Swiss Exchange, Aug 27, 05:30 pm CET
ISIN
CH0019396990
Symbol
YPSN

Ypsomed Stock price

CHF392.00
-43.50 9.99% 1M
+41.50 11.84% 6M
+64.50 19.69% YTD
+5.50 1.42% 1Y
+248.80 173.74% 3Y
+249.60 175.28% 5Y
+285.10 266.70% 10Y
+238.30 155.04% 20Y
SIX Swiss Exchange, Closing price Wed, Aug 27 2025
-10.00 2.49%
ISIN
CH0019396990
Symbol
YPSN

Key metrics

Basic
Market capitalization
CHF5.4b
Enterprise Value
CHF5.7b
Net debt
CHF330.5m
Cash
CHF36.5m
Shares outstanding
13.7m
Valuation (TTM | estimate)
P/E
61.2 | 29.3
P/S
7.1 | 7.5
EV/Sales
7.6 | 7.9
EV/FCF
negative
P/B
7.9
Dividends
DPS
CHF2.20
Yield 1Y | 5Y
0.6% | 0.7%
Growth 1Y | 5Y
10.0% | -
Payout 1Y | 3Y
34.3% | 34.4%
Increased
3 Years
Financials (TTM | estimate)
Revenue
CHF748.9m | CHF715.0m
EBITDA
CHF192.8m | CHF297.4m
EBIT
CHF112.9m | CHF196.4m
Net Income
CHF87.5m | CHF182.7m
Free Cash Flow
CHF-129.0m
Growth (TTM | estimate)
Revenue
36.5% | -4.5%
EBITDA
19.7% | 54.3%
EBIT
30.9% | 74.0%
Net Income
11.6% | 108.8%
Free Cash Flow
-301.8%
Margin (TTM | estimate)
Gross
39.0%
EBITDA
25.7% | 41.6%
EBIT
15.1%
Net
11.7% | 25.6%
Free Cash Flow
-17.2%
Financial Health
Equity Ratio
-
Return on Equity
-
ROCE
13.5%
ROIC
8.3%
Debt/Equity
0.5
More
EPS
CHF6.4
FCF per Share
CHF-9.4
Short interest
-
Employees
3k
Rev per Employee
CHF290.0k
Show more

Is Ypsomed a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Ypsomed Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Ypsomed forecast:

11x Buy
85%
2x Hold
15%

Analyst Opinions

13 Analysts have issued a Ypsomed forecast:

Buy
85%
Hold
15%

Financial data from Ypsomed

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
749 749
37% 37%
100%
- Direct Costs 457 457
39% 39%
61%
292 292
33% 33%
39%
- Selling and Administrative Expenses 126 126
16% 16%
17%
- Research and Development Expense 34 34
10% 10%
4%
193 193
20% 20%
26%
- Depreciation and Amortization 80 80
7% 7%
11%
EBIT (Operating Income) EBIT 113 113
31% 31%
15%
Net Profit 88 88
12% 12%
12%

In millions CHF.

Don't miss a Thing! We will send you all news about Ypsomed directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Ypsomed Holding AG engages in the development and manufacture of injection systems for self-medication of drugs by patients, most notably used to treat diabetes. Its products include DiaExpert, BGMS, OmniPod, YpsoPump & Orbit, Pen needles, Injection systems, and Contract manufacturing. The company operates through the following business segments: Ypsomed Diabetes Care, and Ypsomed Delivery Systems. The Ypsomed Diabetes Care segment owns, manufactures and trade products are marketed under the brand mylife Diabetes care directly to hospitals, physicians, pharmacies and patients via Ypsomed's subsidiaries and distributors. The Ypsomed Delivery Systems segment concerns B2B business and is directly managed by the company. Ypsomed Holding was founded by Wilhelm Michel on December 29, 2003 and is headquartered in Burgdorf, Switzerland.

Head office Switzerland
CEO Simon Michel
Employees 2,600
Founded 2003
Website www.ypsomed.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today